Navigation Links
Savient Pharmaceuticals Reports First Quarter 2009 Financial Results
Date:5/6/2009

roval," said Paul Hamelin, President of Savient. "Early in the quarter, we combined the insights and strategic input of our panel of world class external experts with our internal understanding of this application resulting in our decision to file several key amendments which we believe strengthened and clarified the BLA. The FDA reviewed the amendments and determined that the additional information contained in the submissions constituted major amendments, accepted the amendments to the BLA and elected to extend the current review period and revised our PDUFA date to August 1, 2009. We also took aggressive steps to maintain a stable balance sheet by effectively controlling expenses during the period despite growing resource needs for manufacturing, the approval process and prelaunch preparation. In conjunction with being financially prudent, we successfully completed an important financing in the face of extraordinary market conditions, allowing us to strengthen our cash position as we approach our PDUFA action date. We believe the first quarter of 2009 has been an important transitionary quarter for the Company, resulting in significant progress achieved towards our commitment to bring KRYSTEXXA to the market to treat the disabling aspects of the treatment failure gout population."

Financial Results of Operations for the Three Months Ended March 31, 2009

Total revenues decreased $0.1 million, or 8%, to $1.1 million for the three months ended March 31, 2009, from $1.2 million for the three months ended March 31, 2008. The decrease was due to lower gross product sales of Oxandrin(R), our product that promotes weight gain following involuntary weight loss due to disease or medical condition, as a result of the continued impact of generic competition partially offset by lower provisions for product returns year over year. We expect that revenues from Oxandrin and our authorized generic product oxandrolone will de
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
2. Savients Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
3. Savient Submits Biologics License Application (BLA) for pegloticase
4. Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results
5. Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th
6. Savient Announces Appointment of David Gionco as Chief Financial Officer
7. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2008 Results Conference Call on Thursday, February 26, 2009
8. Savient Pharmaceuticals to Raise $31 Million Through Registered Direct Offering
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... (PRWEB) August 20, 2014 WriteResult®, a ... today that it has expanded its myPROpad™ ePRO tablet ... EQ-5D-5L, one of the most widely used and ... general health status. The EQ-5D is used during clinical ... a measure that can be used to demonstrate Health-Related ...
(Date:8/20/2014)... Bulgaria (PRWEB) August 20, 2014 ... was released today including improvements to the enterprise ... and connectors for Lucene, SOLR and Elasticsearch. This ... for this high performance triplestore – GraphDB™ was ... interested in deploying the only mature enterprise resilient ...
(Date:8/19/2014)... Piscataway, NJ (PRWEB) August 20, 2014 ... engineering and regenerative medicine is an inadequate vascular ... engineered constructs and decellularized tissues is critical for ... Researchers have attempted to mitigate deficiencies in vascularization ... including adding scaffold bioactivity, optimizing scaffold design and ...
(Date:8/19/2014)... August 19, 2014 Shimadzu Scientific ... systems, Prominence-i and Nexera-i, adding to the company’s ... excellent functionality, an intuitive operating environment, and full ... more efficient workflow for conventional to ultra-high-speed analysis. ... intuitive and intelligent design so users can begin ...
Breaking Biology Technology:EQ-5D™ Assessment Now Available for iPad 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3
... ... software (OSS) in clinical trial electronic data capture and clinical data management. , ... Waltham, MA (PRWEB) January ... trial software, will gather on March 22nd, 2010 in Bethesda, Maryland (USA) for the ...
... ... over 24 years of experience to Professional Reprographics. , ... Irvine, California (PRWEB) January 7, 2010 -- Orange ... as President of Professional Reprographics. The naming of Cindy as President reflects Pro Repro’s ...
... , , , , SHENYANG, ... ), a leading biotechnology company focused on researching,developing, manufacturing ... it has submitted its application for a,registrational clinical trial ... Feraheme (ferumoxytol) Injection for intravenous,use. Feraheme is an intravenous ...
Cached Biology Technology:OpenClinica Global Conference to Bring Together Global Community for Open Source Clinical Trials Software 2OpenClinica Global Conference to Bring Together Global Community for Open Source Clinical Trials Software 3OpenClinica Global Conference to Bring Together Global Community for Open Source Clinical Trials Software 4Woman Owned Business President Makes Her Mark at Professional Reprographics 23SBio Inc. Applies for SFDA Registrational Trial for Feraheme(TM) 23SBio Inc. Applies for SFDA Registrational Trial for Feraheme(TM) 33SBio Inc. Applies for SFDA Registrational Trial for Feraheme(TM) 4
(Date:8/19/2014)... must be made to decrease China,s increasing caesarean section ... in BJOG: An International Journal of Obstetrics and ... highest caesarean delivery rates in the world. Of 16 ... caesarean. Although the exact rate is not known, the ... reports total caesarean rates ranging from 36% to 58%. ...
(Date:8/19/2014)... HOUSTON, Aug. 19, 2014 To improve students, ... poor grades, the University of Houston (UH) implemented ... for students at risk for failure. , ... Coordinating Board (THECB), the Department of Biology and ... first-year students taking "General Biology" for non-majors and ...
(Date:8/19/2014)... be used in supermarkets to encourage healthier spending habits? ... answer that very question by tracking the purchasing records ... System to rate the nutritional value of foods for ... Lab,s David Just, PhD, and Brian Wansink PhD, author ... of over 150 Hannaford Supermarkets in the Northeastern United ...
Breaking Biology News(10 mins):Is China's 50 percent cesarean section delivery rate too high? 2Is China's 50 percent cesarean section delivery rate too high? 3University of Houson program earns kudos for improving grades, retaining students 2University of Houson program earns kudos for improving grades, retaining students 3
... advance into the vanishingly small realm of molecules and ... venerable optical microscope, after all. In fact, research at ... that a hybrid version of the optical microscope might ... 10 nanometers—a tiny fraction of the wavelength of visible ...
... simple drug, given to children with severe malaria before they ... researchers in this week's BMJ. , Every year over a ... fatalities occur outside hospital, especially in rural areas. For those ... within 24 hours of admission. , Conventional treatment, given by ...
... potential new drug that inhibits destructive cell signals that ... scientists showed they could block the growth of cultured ... , Their finding, reported in the March 22, 2005, ... is the first step toward developing a new class ...
Cached Biology News:Devising Nano Vision for an Optical Microscope 2Newly Discovered Compound Blocks Known Cancer-Causing Protein 2Newly Discovered Compound Blocks Known Cancer-Causing Protein 3
... The Gene Inspector can perform many sophisticated DNA ... is much more than just another sequence analysis ... entire suite of analyses to be performed each ... design custom style sheets which specify exactly how ...
... extraction through columns is a well-known separation ... Typical applications are in DNA/RNA extraction in ... compound purification in chemical or analytical laboratories. ... the Genesis series instruments for smaller scales. ...
... is a revolutionary new application for ... a novel interface, Expression makes complex ... simple. Expression uses the very latest ... in the way sequences are analysed. ...
Request Info...
Biology Products: